ProAxsis were this week delighted to host His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse III building at Catalyst Inc. Prince Andrew, who is Patron of Catalyst Inc., spent time meeting the team at ProAxsis, as well as finding out more details about the company’s novel ProteaseTag® technology, which allows for the detection and measurement of active protease biomarkers of disease. The company is currently focused on the measurement of neutrophil elastase, as a biomarker of lung infection and inflammation in chronic respiratory diseases, such as cystic fibrosis, bronchiectasis and COPD.
For further information about the company and its core technology, please visit www.proaxsis.com or contact us via firstname.lastname@example.org
ProAxsis is part of the NetScientific group and is one of the group’s core portfolio companies. The company is also supported by QUBIS, the commercialisation arm of Queens University.